scholarly journals Acquired aplastic anaemia in children – Optimal outcomes depend on optimal delivery of immunosuppressive therapy

2016 ◽  
Vol 1 (2) ◽  
pp. S19
Author(s):  
Dhaarani Jayaraman ◽  
Ramya Uppuluri ◽  
Divya Subburaj ◽  
Venkateshwaran ◽  
Revathi Raj
Keyword(s):  
Immunosuppressive Therapy ◽  
Aplastic Anaemia ◽  
Optimal Outcomes

scholarly journals Acquired aplastic anaemia in children – Optimal outcomes depend on optimal delivery of immunosuppressive therapy

2016 ◽  
Vol 1 (2) ◽  
pp. S20-S21
Author(s):  
Dhaarani Jayaraman ◽  
Ramya Uppuluri ◽  
Divya Subburaj ◽  
Venkateshwaran ◽  
Revathi Raj
Keyword(s):  
Immunosuppressive Therapy ◽  
Aplastic Anaemia ◽  
Optimal Outcomes

The effectiveness of immunosuppressive therapy in patients with aplastic anaemia secondary to chemoradiotherapy for cancers

2021 ◽  
Author(s):  
Noriharu Nakagawa ◽  
Ken Ishiyama ◽  
Mikoto Tanabe ◽  
Takeshi Yoroidaka ◽  
Hiroki Mizumaki ◽  
...  
Keyword(s):  
Immunosuppressive Therapy ◽  
Aplastic Anaemia

No evidence for gamma-interferon mediated haematopoietic inhibition by T cells in aplastic anaemia: an observation in the course of immunosuppressive therapy

1987 ◽  
Vol 67 (2) ◽  
pp. 123-127 ◽  
Author(s):  
Takashi Hanada ◽  
Hideshi Yamamura ◽  
Takao Ehara ◽  
Nobuaki Iwasaki ◽  
Reiko Shin ◽  
...  
Keyword(s):  
T Cells ◽  
Immunosuppressive Therapy ◽  
Aplastic Anaemia ◽  
Gamma Interferon

No evidence for gamma-interferon mediated haematopoietic inhibition by T cells in aplastic anaemia: an observation in the course of immunosuppressive therapy

2008 ◽  
Vol 67 (2) ◽  
pp. 123-127
Author(s):  
Takashi Hanada ◽  
Hideshi Yamamura ◽  
Takao Ehara ◽  
Nobuaki Iwasaki ◽  
Reiko Shin ◽  
...  
Keyword(s):  
T Cells ◽  
Immunosuppressive Therapy ◽  
Aplastic Anaemia ◽  
Gamma Interferon

Aplastic anaemia associated with a Philadelphia chromosome and monosomy 7 during immunosuppressive therapy

2003 ◽  
Vol 71 (2) ◽  
pp. 130-132 ◽  
Author(s):  
Atsushi Satoh ◽  
Hiroshi Miwa ◽  
Osami Daimaru ◽  
Norikazu Imai ◽  
Akihito Hiramatsu ◽  
...  
Keyword(s):  
Immunosuppressive Therapy ◽  
Aplastic Anaemia ◽  
Philadelphia Chromosome ◽  
Monosomy 7

scholarly journals Case report of aplastic anaemia detected in third trimester of pregnancy: dilemmas faced

2020 ◽  
Vol 10 (1) ◽  
pp. 381
Author(s):  
Gayathri Dinesh Kamath ◽  
Sunil Prabhakar Udgire ◽  
Divya Katewa
Keyword(s):  
Immunosuppressive Therapy ◽  
Aplastic Anaemia ◽  
Blood Cells ◽  
Multidisciplinary Approach ◽  
Daily Basis ◽  
Normal Vaginal Delivery ◽  
Third Trimester ◽  
Packed Red Blood Cells ◽  
The Third ◽  
Anaemia In Pregnancy

Aplastic anaemia with pregnancy is rarely encountered. Management of aplastic anaemia in pregnancy primarily involves a multidisciplinary approach offering supportive care. Our case was challenging as she developed aplastic anaemia during the third trimester and had refractory thrombocytopenia. She required platelet transfusions on a daily basis for few weeks as well as packed red blood cells frequently. Her leucocyte count was low initially but improved quickly unlike the platelet counts. Initiation of immunosuppressive therapy turned out to be beneficial and culminated in a good outcome. After starting immunosuppressive therapy with eltrombopag and cyclosporine she drifted through term and achieved a normal vaginal delivery.

Acquired aplastic anaemia and pure red cell aplasia

2020 ◽  
pp. 5336-5348
Author(s):  
Judith C.W. Marsh ◽  
Shreyans Gandhi ◽  
Ghulam J. Mufti
Keyword(s):  
Bone Marrow ◽  
T Cells ◽  
Immunosuppressive Therapy ◽  
Aplastic Anaemia ◽  
Pure Red Cell Aplasia ◽  
Dyskeratosis Congenita ◽  
Red Cell ◽  
Red Cell Aplasia ◽  
Immune Mediated ◽  
Long Term Follow Up

Aplastic anaemia (AA) is a rare bone marrow failure (BMF) disorder characterized by pancytopenia and a hypocellular bone marrow. AA is commonly acquired, immune mediated, and idiopathic in nature. Activated autoreactive, cytotoxic CD8+ T cells are present but recent work has shown that CD4+ T cells appear to be more important in the pathogenesis of acquired AA. The immune nature of acquired AA provides the rationale for one of the treatment options, namely immunosuppressive therapy. First-line treatment of acquired AA is either immunosuppressive therapy with antithymocyte globulin and ciclosporin or allogeneic haematopoietic stem cell transplantation (HSCT). Both modalities offer excellent survival. Patients treated with immunosuppressive therapy are at later risk of relapse and clonal evolution to myelodysplastic syndrome and acute myeloid leukaemia, so require long-term follow-up. HSCT, if successful, is curative, but risks include graft rejection, infections, and graft-versus-host disease (GVHD); recent changes to the transplant conditioning regimen have reduced the GVHD risk. The inherited forms of AA include Fanconi’s anaemia, a disorder of DNA repair, dyskeratosis congenita, a disorder of telomere maintenance, and Shwachman–Diamond syndrome, one of the so-called ribosomopathies characterized by defective ribosomal biogenesis. Pure red cell aplasia (PRCA) is a form of BMF characterized by severe anaemia with reticulocytopenia and reduced erythroid progenitors in the bone marrow. PRCA most commonly is an acquired disorder and immune mediated, and often occurs in association with a wide range of conditions. Diamond–Blackfan anaemia, an inherited form of PRCA, is another example of a ribosomopathy, and is caused by mutations in one of many ribosomal protein genes, resulting in haploinsufficiency.

Sign in / Sign up

Export Citation Format

Share Document